Bacteria-driven cancer therapy: Exploring advancements and challenges.

Autor: Din SRU; Department of Microbiology, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China., Saeed S; School of Environment and Science, Griffith University, Nathan, QLD 4111, Australia., Khan SU; Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City and Southwest University, College of Agronomy and Biotechnology, Southwest University, Beibei, Chongqing 400715, China; Engineering Research Center of South Upland Agriculture, Ministry of Education, Chongqing 400715, China; Women Medical and Dental College, Khyber Medical University, Peshawar, KPK 22020, Pakistan., Arbi FM; Quaid-e-Azam Medical College, Bahawalpur, Punjab 63100, Pakistan., Xuefang G; Department of Medical Microbiology, Dalian Medical University, Dalian 116044, China., Zhong M; Department of Microbiology, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China. Electronic address: dalianzhongmintao@163.com.
Jazyk: angličtina
Zdroj: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2023 Nov; Vol. 191, pp. 104141. Date of Electronic Publication: 2023 Sep 22.
DOI: 10.1016/j.critrevonc.2023.104141
Abstrakt: Cancer, a serious fatal disease caused by the uncontrolled growth of cells, is the biggest challenge flagging around medicine and health fields. Conventionally, various treatments-based strategies such as radiotherapy, chemotherapy, and alternative cancer therapies possess drugs that cannot reach the cancerous tissues and make them toxic to noncancerous cells. Cancer immunotherapy has made outstanding achievements in reducing the chances of cancer. Our considerable attention towards cancer-directed immune responses and the mechanisms behind which immune cells kill cancer cells have progressively been helpful in the advancement of new therapies. Among them, bacteria-based cancer immunotherapy has achieved much more attention due to smart and robust mechanisms in activating the host anti-tumor response. Moreover, bacterial-based therapy can be utilized as a single monotherapy or in combination with multiple anticancer immunotherapies to accelerate productive clinical results. Herein, we comprehensively reviewed recent advancements, challenges, and future perspectives in developing bacterial-based cancer immunotherapies.
Competing Interests: Declaration of Competing Interest The author declared that they have no competing interests among them.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: